JARISLOWSKY FRASER Ltd Lowers Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

JARISLOWSKY FRASER Ltd decreased its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 46,247 shares of the company’s stock after selling 413 shares during the quarter. JARISLOWSKY FRASER Ltd’s holdings in Merck & Co., Inc. were worth $5,041,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Norges Bank purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $3,108,366,000. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after purchasing an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Merck & Co., Inc. by 14.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Merck & Co., Inc. by 10,221.4% in the 4th quarter. International Assets Investment Management LLC now owns 2,375,269 shares of the company’s stock worth $258,952,000 after purchasing an additional 2,352,256 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $187,042,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on MRK shares. UBS Group boosted their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a report on Monday, March 11th. Truist Financial boosted their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Finally, Barclays boosted their target price on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.33.

Check Out Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 2.6 %

MRK stock traded down $3.31 during mid-day trading on Tuesday, reaching $126.18. The company had a trading volume of 2,954,892 shares, compared to its average volume of 7,928,501. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market capitalization of $319.59 billion, a PE ratio of 144.02, a price-to-earnings-growth ratio of 1.66 and a beta of 0.39. The firm has a 50 day moving average of $128.31 and a 200 day moving average of $119.98. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.40 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 8.69 earnings per share for the current fiscal year.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.